Where does Morphic Therapeutic, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Morphic Therapeutic, Inc. ranks #20,105 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Morphic Therapeutic, Inc. hold?

Morphic Therapeutic, Inc. holds 14 US utility patents granted between 2020 and 2025, spanning 3 technology areas.

What is Morphic Therapeutic, Inc.'s Innovation Score?

Morphic Therapeutic, Inc. has an Innovation Score of 34.5 out of 100 (48th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Morphic Therapeutic, Inc. focus on?

Morphic Therapeutic, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 14 patents, ranking #603 of 3,165 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

Is Morphic Therapeutic, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Morphic Therapeutic, Inc..

What does claim depth mean for Morphic Therapeutic, Inc.'s patents?

Morphic Therapeutic, Inc.'s patents average 23.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Morphic Therapeutic, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Morphic Therapeutic, Inc.

USPTO PatentsView assignee record - 14 granted patents across 3 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Morphic ranks #20,105 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 3 technology areas.

#20,105
of 49,997 US assignees by volume: 48th percentile
by Innovation Score (34.5/100): 23.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R20105 · US Corporation #20,105 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 14 grants
MID-PACK #20,105/49,997
PHOTO-FINISH Molonlave Group
CPC-NARROW C07D · 3 areas
INNOV-THIN 34.5/100
CLAIMS-DENSE 23.8 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Molonlave Group LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Morphic’s 34.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (27%) Velocity 4.8 pts (14%) Breadth 6.1 pts (18%) Claim depth 14.3 pts (41%)

Qualcomm Incorporated · highest

85
Morphic Therapeutic · this assignee

35
3D Lighting… · lowest

7

What this shows Morphic's Innovation Score is 34.5/100 (48th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Morphic?

Each dot is one of Morphic’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Morphic’s own 23.8 claims/patent is ABOVE the 14.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Morphic vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Morphic's grants concentrate

Morphic Therapeutic, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2021 (6 grants) versus a trough of 1 in 2020. By volume, Morphic sits between Molonlave Group LLC and Nakamura-tome Precision Industry Co., Ltd..

Morphic's three-year grant acceleration

Morphic Therapeutic, Inc. shows 5 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Molonlave Group

14
Monster Energy

14
Montres Jaquet Dr…

14
Morega Systems

14
Multi-color

14
Multiquip

14
NAC International

14
Nakamura-tome Pre…

14
Morphic Therapeut… ◀

14

What this shows Morphic holds 14 patents at rank #20,110, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Morphic

By rank, the assignees closest to #20,110 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Morphic's primary technology class.

Morphic's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 48th percentile higher than 48% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Morphic Therapeutic, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	7.1%
2021	6	42.9%
2022	1	7.1%
2023	3	21.4%
2024	1	7.1%
2025partial year	2	14.3%

Which technologies does Morphic Therapeutic, Inc. patent most?

C07D - Heterocyclic Compounds 14

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Morphic Therapeutic, Inc.'s patent record in context - here's where to go next.

Morphic Therapeutic, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #20,105 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Morphic Therapeutic, Inc. against Molonlave Group LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.